PLASMA CORTISONE IN THE METABOLIC SYNDROME

代谢综合征中的血浆可的松

• 批准号: 7376635
• 负责人: ROGER J GREKIN
• 金额: $ 3.53万
• 依托单位: UNIVERSITY OF MICHIGAN AT ANN ARBOR
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-04-05 至 2007-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7376635
• 关键词: adipocytes; blood pressure; cortisol; fats; kidney; metabolic syndrome; obesity; plasma; potassium; salts

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The active form of cortisone is cortisol, a substance made in the adrenal glands. Cortisol is inactivated by the kidney to form inactive cortisone, and cortisone is reactivated in liver and fat tissue to reform active cortisol. Recent evidence suggests that fat cells in obese individuals have increased activity of the enzyme that reactivates cortisone. Since overproduction of cortisol causes abdominal obesity, it is possible that overactivity of this reactivation process is responsible for worsening obesity in some individuals. In order to determine the importance of this pathway, we plan to block the formation of cortisone in the kidney using a licorice extract. If reactivation of cortisone in fat cells is important in causing abdominal obesity, inhibition of cortisone formation should cause a decrease in abdominal fat. We will study twelve women with abdominal obesity. Six subjects will be treated with licorice extract for six months and the other six subjects will receive pills which do not contain medication for six months. Each subject will participate in an exercise program and will follow a diet. We will measure weight, abdominal and total body fat content, sugar, insulin, cholesterol and blood pressure before treatment and during treatment. Known side effects of licorice include salt retention, increased blood pressure and potassium loss. In order to prevent these side effects, we will administer spironolactone along with the licorice extract. Spironolactone is an effective inhibitor of the hypertensive, salt retaining and potassium wasting effects of licorice.

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子弹和调查员（PI）可能已经从其他NIH来源获得了主要资金，因此可以在其他清晰的条目中代表。列出的机构适用于该中心，这不一定是调查员的机构。可的松的活性形式是皮质醇，一种在肾上腺中生产的物质。皮质醇被肾脏灭活以形成无活性可的松，并在肝脏和脂肪组织中重新激活可的松以改革活性皮质醇。最近的证据表明，肥胖个体中的脂肪细胞的活性增加了可重新激活可的松的酶。由于皮质醇过量产生腹部肥胖，因此这种重新激活过程的过度活动可能导致某些个体的肥胖症恶化。为了确定该途径的重要性，我们计划使用甘草提取物阻止肾脏中可的松的形成。如果在脂肪细胞中可可的可可重新活化在引起腹部肥胖症中很重要，则可皮质酮形成的抑制作用应导致腹部脂肪减少。我们将研究十二名腹部肥胖症的女性。六名受试者将用甘草提取物治疗六个月，而其他六名受试者将获得六个月不含药物的药丸。每个受试者将参加锻炼计划，并遵循饮食。我们将在治疗前和治疗过程中测量体重，腹部和总体内脂肪含量，糖，胰岛素，胆固醇和血压。甘草的已知副作用包括保留盐，血压升高和钾损失。为了防止这些副作用，我们将与甘草提取物一起管理螺内酯。螺内酯是甘草的高血压，盐保留和钾浪费作用的有效抑制剂。